Struggling Between Liver Transplantation and Portopulmonary Hypertension.
Heart Fail Clin
; 19(1): 55-65, 2023 Jan.
Article
em En
| MEDLINE
| ID: mdl-36435573
ABSTRACT
Portopulmonary hypertension (PoPH) is a progressive, ultimately fatal cardiopulmonary disease that occurs exclusively in patients with underlying portal hypertensive liver disease. PoPH outcomes are driven by both the severity of underlying liver disease and the degree of cardiac adaptation to elevated pulmonary pressures. The mainstay of treatment in PoPH is targeted pulmonary vascular therapy. Liver transplantation (LT) can be beneficial in some patients, but is associated with considerable risks in the PoPH population, and outcomes are variable. The optimal management strategy for PoPH, LT, or medical therapy alone, is unclear, and further research is needed to help guide clinical decision-making.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transplante de Fígado
/
Hipertensão Portal
/
Hipertensão Pulmonar
Limite:
Humans
Idioma:
En
Revista:
Heart Fail Clin
Ano de publicação:
2023
Tipo de documento:
Article